NAPM Plans To Reiterate Generic Equivalency To MD Groups: AMA, AAP
The National Association of Pharmaceutical Manufacturers is seeking meetings with professional medical societies to reiterate the message that generic drugs are therapeutically equivalent to reference brands.
You may also be interested in...
Exclusivity extensions under FDAMA's pediatric provisions will not cause "irreparable harm" to generic drug manufacturers, D.C. Federal Court Judge James Robertson maintained in an April 20 denial of a generics industry motion for preliminary injunction.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials